Pertussis Vaccine Market Size, Share, Growth, And Industry Analysis By Type (Whole-cell Vaccines, Acellular Vaccines) By Application (12 Months Below, 12 Months Above), Regional Outlook, and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

PERTUSSIS VACCINE MARKET OVERVIEW

The global pertussis vaccine market, value at USD 6.12 Billion in 2026 and reach USD 8.34 Billion by 2035 maintaining a CAGR of 3.5% from 2026 to 2035.

The respiratory disease pertussis, sometimes referred to as whooping cough, affects the nose and throat. Although it has been present for centuries, vaccinations can prevent it. The whooping cough-causing Borrelia bacteria are protected from by the pertussis vaccination, which is administered intravenously. It has a toxin that has been rendered inactive but is still found in Bordetella pertussis cells. The respiratory infection pertussis, usually known as whooping cough, is brought on by the bacteria Bordetella pertussis. Numerous quick coughing fits accompanied by an inspiratory whoop and vomiting following coughing fits are among the symptoms.

Adults can also have the DTP vaccine if they want to strengthen their immunity or if they are prone to diphtheria. Similar to this, pregnant women must receive a dose of the DTP vaccine throughout the last trimester of pregnancy to ensure that the unborn child continues to be protected from the diseases.

KEY FINDINGS

COVID-19 Impact

Shift Of Focus By CORONA Causes Market Growth To Be Hampered

The global COVID-19 pandemic has been unprecedented and staggering, with pertussis vaccine market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The dynamics of the market were altered by the COVID-19 epidemic. Since the focus changed from routine immunizations to COVID-19 vaccines in recent years, there has been a minor decline in the market for conventional vaccines. A significant amount of work has gone into creating novel medications and vaccines to combat the virus. Following several weeks of investigation, businesses have begun developing medications and therapies to combat the virus.

Latest Trends

Pharmaceutical Businesses' Initiatives For Expanding And Growing The Market

Due to rising public awareness of the benefits of DTP vaccines worldwide, particularly in developing countries, the market for DTP vaccines is predicted to expand steadily throughout the projected period.

Increased efforts by pharmaceutical companies to improve vaccine R&D are projected to support the market growth for DTP vaccines. Additionally, cooperation among those involved in the vaccine business is crucial in order to combine all available product development strategies and raise the likelihood that immunization will be made widely available.

• According to the World Health Organization, about 109 million infants globally received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine in 2024, representing 85% global coverage among one-year-old children. However, around 14.3 million infants remained “zero-dose” children, meaning they did not receive even the first routine vaccine dose. These figures indicate increasing global focus on restoring routine immunization programs, which is directly influencing demand for pertussis-containing vaccines in national vaccination schedules.
• According to data published by the Pan American Health Organization, approximately 88% of children under one year in the Americas received three doses of DTP3 vaccine in 2023, covering around 13.5 million infants in the region. Health authorities are increasingly emphasizing booster immunization programs for adolescents and adults to address waning immunity, which is driving adoption of combination pertussis vaccines in routine immunization programs.

Download Free Sample to learn more about this report

PERTUSSIS VACCINE MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into Whole-cell Vaccines, Acellular Vaccines. Whole-cell Vaccines will be anticipated to be the leading segment.

• Whole-cell Vaccines: Whole-cell vaccines use the entire bacterium or virus (killed or weakened) to trigger a strong and broad immune response. Because they present many natural antigens to the immune system, they often produce long-lasting immunity but may cause more side effects.
• Acellular Vaccines: Acellular vaccines contain only specific purified components of a pathogen, such as proteins or sugars, rather than the whole organism. This targeted approach reduces side effects while still stimulating protective immunity against the disease.

By Application Analysis

Based on application, the market can be divided into 12 Months Below, 12 Months Above. 12 Months Below vaccines will dominate the market.

• 12 Months Below: Experiences from the past year serve as quiet teachers, shaping resilience in subtle ways. Even in challenges, growth quietly blooms, laying the foundation for future triumphs.
• 12 Months Above: The year ahead gleams with possibilities, each day a canvas for new achievements. Ambitions rise like the sun, promising momentum, discovery, and extraordinary milestones.

Driving Factors

Increasing Incidence Of Newly Discovered And Rediscovered Infectious Diseases

Living in more densely populated places, travelling much more frequently and over longer distances than in the past, and increasing human-wildlife contact raise serious concerns about the potential for new infectious diseases to spread quickly and trigger pandemics over the world. Additionally, there is a chance that illnesses could spread after being purposefully introduced into an animal, human, or plant population for malicious objectives. Future pandemics and outbreaks could be even deadlier than COVID-19, experts have warned. In the upcoming years, there will continue to be an increasing need for vaccines due to the increasing prevalence of these contagious diseases. In order to assure stronger R&D funding initiatives, a solid pipeline, and new vaccine opportunities for wide population segments and promote market growth, variables including the advent of new diseases are necessary.

• According to the World Health Organization, vaccination programs prevent 4–5 million deaths annually from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. Pertussis remains a major public health concern, particularly among infants, which is prompting governments to strengthen immunization policies and expand access to pertussis-containing vaccines. The continued presence of millions of vulnerable infants worldwide strongly supports the growth of the pertussis vaccine market.
• According to global immunization assessments cited in public health literature, the annual global birth cohort is approximately 135–145 million children, all of whom require routine vaccinations including pertussis-containing vaccines. With most national immunization programs recommending at least 3 primary doses during infancy, the demand for pertussis vaccines remains consistently high across both developed and developing healthcare systems.

Increasing Awareness Spurs Market Growth

A viral illness called pertussis produces intense, uncontrollable coughing that makes you throw up and has trouble breathing. For young children, this illness may pose a life-threatening concern. Despite the availability of immunizations, this infection has considerably grown over the last few years because parents and guardians are less aware of the benefits of pertussis vaccination. Factors like improving vaccination rates and increased vaccination knowledge in developing nations worldwide.

A major element for market expansion is the rising incidence of immunization, particularly for kids to maintain a healthy lifestyle. The market for pertussis vaccines is expanding as a result of the rising birthrate everywhere in the world.

Restraining Factors

High Expense Of Developing Vaccines Affects Market Growth

The process of developing vaccines requires a significant amount of capital. The cost of storing and shipping vaccinations is higher than that of any other pharmaceutical product because they need specific facilities and monitoring systems. The effectiveness and quality of vaccines can suffer from inadequate storage and delivery infrastructure. From in vitro research to marketing, the development process takes 10 to 15 years and costs between US$800 million and US$1 billion. Additionally, because vaccine research has a poor success rate, businesses struggle to control operational expenses and secure initial investments. Therefore, the high cost of vaccine production and storage is limiting market expansion.

• According to the World Health Organization, about 14.3 million infants worldwide did not receive even the first dose of a DTP vaccine in 2024, highlighting major gaps in healthcare access and immunization infrastructure. These access barriers are particularly pronounced in low-income and conflict-affected regions, limiting vaccine distribution and slowing overall market penetration.
• Global health data indicate strong disparities in vaccination coverage. For example, pertussis-containing vaccine coverage reached approximately 95% in Europe, while it was estimated at only 74% in Africa. Such regional disparities reflect supply chain limitations, funding constraints, and health system challenges that can restrict the growth of pertussis vaccination programs.
• Download Free Sample to learn more about this report

•  

PERTUSSIS VACCINE MARKET REGIONAL INSIGHTS

North America to Dominate Market Share During 2023-2031

The market is essentially divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa based on region. North America held the highest share of the market in 2020. The market in North America is driven by elements including required reporting and an increase in the occurrence of infectious diseases. The markets in Europe and Asia Pacific are next to the North American market.

Due to the region's quick population expansion, rising vaccination rates, and rise in infectious disease prevalence, growth in Asia Pacific is anticipated to be faster than elsewhere. These factors are anticipated to drive the need for pertussis vaccines. Thailand has 99% of the pertussis vaccine coverage in the Asia Pacific region, followed by Japan and China with 98% and 97%, respectively.

Key Industry Players

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Sanofi Pasteur (France): According to multiple market analysis sources, Sanofi Pasteur holds approximately 19% of the global pertussis vaccine market share in terms of global supply and distribution of pertussis‑containing vaccines.
• GlaxoSmithKline (U.K.): Market data shows that GSK accounts for about 17% of the global pertussis vaccine market share, reflecting its strong presence through DTaP and Tdap vaccine offerings.

List Of Top Pertussis Vaccine Companies

• Sanofi Pasteur (France)
• GSK (U.K.)
• Mitsubishi Tanabe Pharma (Japan)
• Wuhan Institute of Biological Products (China)
• Walvax Biotechnology
• Minhai Biotechnology (China)
• KM Biologics (Japan)
• Chengdu Institute of Biological Products (China)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.